TY - JOUR
T1 - Subcutaneous implantable cardioverter-defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia
T2 - A transatlantic experience
AU - Orgeron, Gabriela M.
AU - Bhonsale, Aditya
AU - Migliore, Federico
AU - James, Cynthia A.
AU - Tichnell, Crystal
AU - Murray, Brittney
AU - Bertaglia, Emanuele
AU - Cadrin-Tourigny, Julia
AU - De Franceschi, Pietro
AU - Crosson, Jane
AU - Tandri, Harikrishna
AU - Corrado, Domenico
AU - Calkins, Hugh
N1 - Publisher Copyright:
© 2018 The Authors.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Background-Despite growing use of the subcutaneous implantable cardioverter-defibrillator (S-ICD), its clinical role in arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) patients remains undefined. We aim to elucidate the cardiac phenotype, implant characteristics, and long-term efficacy regarding appropriate therapy and complications in ARVC/D patients with an S-ICD implant. Methods and Results-A transatlantic cohort of ARVC/D patients who underwent S-ICD implantation was analyzed for clinical characteristics, S-ICD therapy, and long-term outcome including device-related complications. The cohort included 29 patients (52% male, 76% probands, 59% with ARVC/D-associated mutation, 59% primary prevention [no prior sustained ventricular arrhythmias], and 45% first-generation S-ICD devices). At implant, all inducible patients (27/29) had conversion of induced ventricular fibrillation. Two patients (7%) had superficial infections of the incision site that were treated conservatively. Over amedian follow-up of 3.16 years (interquartile range: 2.21-4.51 years), all episodes (6 patients, 4% per year) of sustained ventricular arrhythmias were appropriately detected and treated. Six patients (21%) experienced 39 inappropriate shocks, with 3 requiring device explantation. Oversensing of noncardiac signal (n=4; especially myopotentials) and cardiac signal (n=4) was the most frequent etiology. No lead or device dislodgement, infection, skin erosion, or explantation related to need for antitachycardia pacing was noted. Conclusions-S-ICD can effectively treat both induced and spontaneous ventricular arrhythmias in patients with ARVC/D. The rate of inappropriate shocks, although considerable, is comparable to that in ARVC/D patients treated with transvenous ICDs. When they occurred, inappropriate shocks were primarily due to cardiac and, uniquely, noncardiac oversensing. We suggest potential strategies for minimizing inappropriate therapy.
AB - Background-Despite growing use of the subcutaneous implantable cardioverter-defibrillator (S-ICD), its clinical role in arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) patients remains undefined. We aim to elucidate the cardiac phenotype, implant characteristics, and long-term efficacy regarding appropriate therapy and complications in ARVC/D patients with an S-ICD implant. Methods and Results-A transatlantic cohort of ARVC/D patients who underwent S-ICD implantation was analyzed for clinical characteristics, S-ICD therapy, and long-term outcome including device-related complications. The cohort included 29 patients (52% male, 76% probands, 59% with ARVC/D-associated mutation, 59% primary prevention [no prior sustained ventricular arrhythmias], and 45% first-generation S-ICD devices). At implant, all inducible patients (27/29) had conversion of induced ventricular fibrillation. Two patients (7%) had superficial infections of the incision site that were treated conservatively. Over amedian follow-up of 3.16 years (interquartile range: 2.21-4.51 years), all episodes (6 patients, 4% per year) of sustained ventricular arrhythmias were appropriately detected and treated. Six patients (21%) experienced 39 inappropriate shocks, with 3 requiring device explantation. Oversensing of noncardiac signal (n=4; especially myopotentials) and cardiac signal (n=4) was the most frequent etiology. No lead or device dislodgement, infection, skin erosion, or explantation related to need for antitachycardia pacing was noted. Conclusions-S-ICD can effectively treat both induced and spontaneous ventricular arrhythmias in patients with ARVC/D. The rate of inappropriate shocks, although considerable, is comparable to that in ARVC/D patients treated with transvenous ICDs. When they occurred, inappropriate shocks were primarily due to cardiac and, uniquely, noncardiac oversensing. We suggest potential strategies for minimizing inappropriate therapy.
KW - Arrhythmogenic right ventricular cardiomyopathy
KW - Implanted cardioverter defibrillator
KW - Long-term follow-up
KW - Ventricular tachycardia
UR - http://www.scopus.com/inward/record.url?scp=85056897653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056897653&partnerID=8YFLogxK
U2 - 10.1161/JAHA.118.008782
DO - 10.1161/JAHA.118.008782
M3 - Article
C2 - 30608223
AN - SCOPUS:85056897653
SN - 2047-9980
VL - 7
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 21
M1 - e008782
ER -